摘要 |
The present invention provides for the treatment of cancers, e.g., carcinomas, using the ectodomain of syndecan 1, where the ectodomain lacks heparan sulfate residues. In addition, agents that bind the ectodomain of syndecan 1 also are useful as anti-cancer therapeutics.
|